Table 3 Association of Polymorphisms cMyc-N11S and p27-V109G with Tumor Characteristics (N = 967)
From: Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis
| Â | T Stage1 | Nodal Involvement | Grade | Estrogen Receptor2 | ||||
|---|---|---|---|---|---|---|---|---|
| Â | Low (N = 607) | High (N = 315) | None (N = 538) | >= 1 (N = 356) | I (N = 196) | II&III (N = 710) | Negative (N = 279) | Positive (N = 659) |
cMyc-N11S (A>G) | Â | Â | Â | Â | Â | Â | Â | Â |
AA | 553(92.6%) | 279(89.7%) | 490(91.9%) | 315(91.0%) | 174(90.2%) | 642(92.2%) | 249(90.2%) | 600(92.6%) |
AG/GG | 44 (7.4%) | 32 (10.3%) | 43 (8.1%) | 31 (9.0%) | 19 (9.8%) | 54 (7.8%) | 27 (9.8%) | 48 (7.4%) |
p-value | 0.13 | Â | 0.64 | Â | 0.35 | Â | 0.23 | Â |
p27-V109G (T>G) | Â | Â | Â | Â | Â | Â | Â | Â |
TT | 371(62.8%) | 177(56.9%) | 334(63.1%) | 197(57.4%) | 116(60.7%) | 423(61.1%) | 166(59.9%) | 399(62.3%) |
TG | 198(33.5%) | 109(35.1%) | 174(32.9%) | 122(35.6%) | 66 (34.6%) | 234(33.8%) | 99 (35.7%) | 206(32.2%) |
GG | 22 (3.7%) | 25 (8.0%) | 21 (4.0%) | 24 (7.0%) | 9 (4.7%) | 35 (5.1%) | 12 (4.3%) | 35 (5.5%) |
p-value | 0.01 | Â | 0.07 | Â | 0.97 | Â | 0.50 | Â |